Observation of Efficacy of Internet-Based Chronic Disease Management Model Combined with Modified Therapy of Bushenyiliu Decoction in Treating Patients with Type 2 Diabetes Mellitus and Prostate Cancer and Its Effect on Disease Control Rate

Developing a Core Outcome Set for Assessing Clinical Safety Outcomes of Prostate Cancer in Clinical Trials of Traditional Chinese Medicine: Protocol for a Mixed Methods Study

BACKGROUND

Among the common malignant tumors in men worldwide, the incidence of prostate cancer ranks second to lung cancer. This disease will bring an economic burden to patients and their families and can reduce the quality of life of patients. Researchers have conducted numerous clinical trials on the efficacy and safety of different interventions in the treatment of prostate cancer with traditional Chinese medicine (TCM) combined with standard treatment regimens. However, the currently published clinical trials exhibit inconsistent and irregular reporting of outcome measures.

OBJECTIVE

The objective of this paper is to emphasize the need for a core outcome set (COS) to facilitate future prostate cancer research, aiming to improve the quality of trials and generate high-quality evidence.

METHODS

This mixed methods project has three phases, as follows: (1) a scoping review of the literature to identify outcomes that have been reported in clinical trials and systematic reviews of interventions involving TCM for the treatment of prostate cancer as well as a qualitative component using interviews to obtain the views of patients with prostate cancer, their families, and their caregivers who have a history of TCM treatment; (2) a Delphi survey among stakeholders to prioritize the core outcomes-Participants will include traditional Chinese and Western medicine clinicians in prostate cancer-related directions, nurses, and methodology experts who will participate in 2 rounds of the Delphi method expert consultation to score each outcome in the list of outcome indicators; and (3) a face-to-face consensus meeting to discuss and agree on the final COS for the application of TCM in the treatment of prostate cancer.

RESULTS

The protocol has been registered in PROSPERO (CRD42022356184) before the start of the review process, and we will initiate the review on August 1, 2023; results should be expected by September 1, 2023. The Delphi survey among stakeholders is expected to start in October 2023.

CONCLUSIONS

The development of a core outcome set for assessing clinical safety outcomes of prostate cancer in clinical trials of TCM will provide a significant first step to assist Chinese doctors, researchers, and policy makers.

TRIAL REGISTRATION

PROSPERO CRD42022356184; https://tinyurl.com/ysakz74r.

INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID)

PRR1-10.2196/46794.

Diagnostic Value of Emission Computed Tomography Combined with Computed Tomography for Metastatic Malignant Tumor of Spine

Objective

To explore the diagnostic value of emission computed tomography (ECT) combined with computed tomography (CT) for metastatic malignant tumor of spine.

Methods

By means of retrospective study, a total of 102 patients with extraskeletal primary malignant tumor treated in our hospital from February 2019 to February 2021 were selected as the subjects. All patients had single lesion of the spine, of which 72 were malignant and 30 were benign according to the results of pathological examination. ECT and CT examinations were performed to all patients, and by taking the pathological findings as the gold standard, the sensitivity, specificity, positive predictive value and negative predictive value of ECT, CT, and their combination were calculated, and their efficacy in diagnosing metastatic malignant tumor of spine was analyzed.

Results

A total of 68 (94.4%) metastatic malignant spinal tumors were detected by ECT combined with CT, with a detection rate of 100% in breast cancer and lung cancer, 94.1% in liver cancer, and 78.6% in prostate cancer, respectively; the combined diagnosis had a diagnostic sensitivity of 94.4%, specificity of 73.3%, positive predictive value of 89.5%, negative predictive value of 84.6%, and diagnostic accuracy rate of 88.2%, and AUC (95% CI) = 0.839 (0.739-0.939).

Conclusion

Combining ECT with CT has a good diagnostic efficacy for metastatic malignant spinal tumors.